Table 1 Clinical trials with BTK inhibitors in B cell malignancies
From: Role of Bruton’s tyrosine kinase in B cells and malignancies
Patient population | Therapeutic regimen | Phase | Efficacy | Ref |
|---|---|---|---|---|
R/R CLL | Ibrutinib | Ib/II | ORR (71%), PR(20%) | [11] |
R/R CLL | Ibrutinib | III | ORR (63%) | [248] |
TN CLL | Ibrutinib | Ib/II | ORR (85%), CR(26%) | [199] |
TN CLL | Ibrutinib | III | ORR (86%), CR(4%) | [13] |
R/R MCL | Ibrutinib | II | ORR (68%), CR(21%) | [187] |
R/R MCL | Ibrutinib | III | ORR (72%), CR(19%) | [249] |
R/R WM | Ibrutinib | II | ORR(91%), Major response (73%) | [188] |
R/R ABC-DLBCL | Ibrutinib | II | ORR (37%) | [196] |
R/R CLL | Ibrutinib-Rituximab | II | ORR (95%), CR(8%) | [250] |
R/R CLL | Ibrutinib-bendamustine-rituximab | III | ORR (83%), CR(10%) | [251] |
R/R MCL | Ibrutinib-Rituximab | II | ORR (88%), CR(44%), PR(44%) | [252] |
R/R CLL | Acalabrutinib | I/II | ORR(95%) | [12] |
R/R | Acalabrutinib | II | ORR (81%), CR (40%), PR(41%) | [219] |
R/R CLL | ONO/GS-4059 | I | ORR(96%) | [222] |
R/R MCL | ONO/GS-4059 | I | ORR(92%) | [222] |
R/R non-GCB DLBCL | ONO/GS-4059 | I | ORR(92%) | [222] |
R/R CLL | BGB-3111 | I | ORR(90%) | |
R/R MCL | BGB-3111 | I | ORR(80%) | [253] |
R/R MZL | Ibrutinib | II | ORR(51%) | [254] |
R/R FL | Ibrutinib | I | ORR(38%) | [186] |